Horizons expand for FeRx' magnetic drug delivery
This article was originally published in Clinica
FeRx' drug delivery technique, which uses magnetic fields to target pharmaceuticals to specific areas of the body, could have an application in the treatment of bladder cancer, preclinical results have shown. In addition, said the company, evidence is available to show that the method may be broadly applicable as carriers for a wide range of pharmaceutical agents, including peptides and proteins.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.